CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors
Cytochrome P-450 CYP3A
Protein Kinase Inhibitors
As an in vivo phenotypic probe of CYP3A, midazolam oral clearance may have utility for prediction of gefitinib exposure and dose selection. A pharmacokinetic model incorporating this indicator of CYP3A activity has potential for optimization of treatment with gefitinib and other TK inhibitors that are metabolized in a similar manner.